Tp53

Thursday, 04 November 2021

TP-2

Hit it hard from the back
Roll around on the front
I know you've heard a lot of tracks
But 12 Play is what you want
Just let me call the studio
Then we can go all night
Girl I hope you can hang
Cause I'm horny as hell tonight
Taking off your Secrets with my teeth
Slightly rough to let you know it's about to get kinky
Three
Blind your eyes, then I walk you to my bedroom
Four
Now open your eyes
Surprise you've entered twelve play two
Stop
We need to catch our breath
We've been going for a while
It's been about two hours
And we're still going round for round
The water's getting cold
And the movie's going off
This is how we do in TP-2
Five
I'm about to take you for a ride
Now feel it come inside
Baby it's as hard as a brick
Tell me can you feel this sh, sh, sh
Seven
That's when to slow it down
Cause I'm not ready to
Eight
We're almost at the peak
Cause I'm feeling tingly
Now flew your body like, what (what, what)
It's like diamonds with the cut (cut, cut)
The hottest out of your friends
The way you take it from me
Girl you put it on me like draws
Moaning when you talk
I'm about to tear your shit out
New millennium style
Nine
Lookin' you in your eyes
As I'm about to do that thing
Then on down to your thighs
I'm gonna make you scream
Eleven
Now put your body on top of me
I'm about to grab your waist
Twelve
Now quick before we get to thirteen

Latest News for: tp53

Edit

Correlations Between p53 Sequence Differences and Species Lifespan

Technology Org 10 Sep 2021

The protein p53 is a cancer suppressor, produced from the gene TP53. Large mammals such as elephants maintain a low risk of cancer, despite having many more cells than smaller mammals, in part via having many copies of TP53 in the genome.

Edit

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia (Trillium Therapeutics Inc)

Public Technologies 09 Aug 2021

TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine.

Edit

Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML (Aprea Therapeutics Inc)

Public Technologies 21 Jul 2021

Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML ... Prior clinical trials evaluating post-transplant outcomes in TP53 mutant MDS and AML patients have reported a 1-yearpost-transplant RFS of ~30% and a median OS of ~5-8 months.

Edit

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia (Trillium Therapeutics Inc)

Public Technologies 06 Jul 2021

). CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX ... Ingmar Bruns, Trillium's Chief Medical Officer ... Approximately 50 elderly patients (≥75 years old) or patients unfit for intensive induction chemotherapy with newly diagnosed TP53-wild type AML will be enrolled ... Bruns ... About Trillium Therapeutics ... Mike Beyer.

Edit

Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant ...

Nasdaq Globe Newswire 16 Jun 2021

APRE), a biopharmaceutical company focused on developing and commercializing novel cancer ...

Edit

Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 ...

Tyler Morning Telegraph 16 Jun 2021

“We are pleased with these results from the combination of eprenetapopt with venetoclax and azacitidine in this very difficult-to-treat TP53 mutant AML population, a patient group with significant unmet medical need,” said Eyal Attar, M.D., Chief Medical Officer of Aprea Therapeutics.

Edit

Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint (Aprea Therapeutics Inc)

Public Technologies 16 Jun 2021

'We are pleased with these results from the combination of eprenetapopt with venetoclax and azacitidine in this very difficult-to-treat TP53 mutant AML population, a patient group with significant unmet medical need,' said Eyal Attar, M.D., Chief Medical Officer of Aprea Therapeutics.

Edit

TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment [Immunology ...

PNAS 04 Jun 2021

About 70% of all PDAC cases harbor mutations in the TP53 tumor ...

Edit

Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic

Business Wire 22 Apr 2021

SAN DIEGO--(BUSINESS WIRE)--Illumina and Kartos Therapeutics announce a new partnership to co-develop a TP53 CDx based on the TruSight™ Oncology 500 (TSO 500) assay ... .

Edit

Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic (Illumina Inc)

Public Technologies 22 Apr 2021

are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina's comprehensive genomic profiling assay, TruSight™ Oncology 500 (TSO 500) ... inhibitor that activates p53 to drive tumor cell death in TP53 wild-type cancers.

Edit

Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 ...

Nasdaq Globe Newswire 28 Dec 2020

... of the primary data cut from its Phase 3 clinical trial evaluating the safety and efficacy of eprenetapopt with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS).

Edit

Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS) (Aprea Therapeutics Inc)

Public Technologies 28 Dec 2020

'Though we are disappointed the topline results did not reach statistical significance, we continue to believe that eprenetapopt can offer clinical benefit to patients with TP53 mutant malignancies,' said Dr ... About the Phase 3 Trial in TP53 Mutant MDS ... mutations in the TP53 gene.

Edit

TP53 Abnormalities - Response to Flotetuzumab in AML (Rutella) (MacroGenics Inc)

Public Technologies 07 Dec 2020

TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia ... Patients with TP53 mutations ... All 15 patients with TP53 mutations/17p abnormalities were treated on the study and included in clinical analyses ... TP53 Mutations Associate with High Immune Infiltration in TCGA-AML.

Edit

Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant ...

Nasdaq Globe Newswire 30 Nov 2020

... granted Fast Track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukemia (AML).

Edit

Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML) (Aprea Therapeutics Inc)

Public Technologies 30 Nov 2020

Food and Drug Administration (FDA) has granted Fast Track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukemia (AML) ... A pivotal Phase 3 clinical trial of eprenetapopt and azacitidine for frontline treatment of TP53 mutant MDS is ongoing.